

Cover image: Expression of RANK ligand in the spinous process in a patient with ankylosing spondylitis and a patient with degenerative disk disease. See p1338

#### Editor

Tore K Kvien

#### Associate Editors

Francis Berenbaum

Hans Bijlsma

Dimitrios Boumpas

Gerd Burmester

Mary Crow

Iain McInnes

#### Editorial office

Annals of the Rheumatic Diseases

BMJ Publishing Group Ltd

BMA House

Tavistock Square

London WC1H 9JR, UK

T: +44 (0)20 7383 6250

F: +44 (0)20 7383 6668

E: [ard@bmj.com](mailto:ard@bmj.com)

ISSN: 0003-4967 (print)

ISSN: 1468-2060 (online)

Impact Factor: 7.188

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2009 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd, typeset by The Charlesworth Group and printed in the UK on acid-free paper from sustainable forests by Cambrian Printers Limited, Aberystwyth, UK

*Annals of the Rheumatic Diseases* (USPS No: 002-152) is published monthly by BMJ Publishing Group and distributed in the USA by Pitney Bowes International Mailing Services Inc as mailing agent. Periodicals postage paid at Kearny, NJ, USA. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, PB International Mailing Services Inc, 500 US Hwy 46, Clifton, NJ 07011, USA.

## Editorial

- 1237** How to dose infliximab in rheumatoid arthritis: new data on a serious issue  
*R F van Vollenhoven*

## Review

- 1240** European biologicals registers: methodology, selected results and perspectives  
*A Zink, J Askling, W G Dixon, L Klareskog, A J Silman, D P M Symmons*

## Clinical and epidemiological research

- 1247** Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor  $\alpha$  antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study  
*P J Mease, K Hobbs, A Chalmers, H El-Gabalawy, A Bookman, E Keystone, D E Furst, P Ankesaria, A E Heald*
- 1255** The sensitivity to change for lower disease activity is greater than for higher disease activity in rheumatoid arthritis trials  
*B Zhang, M Lavalley, D T Felson*
- 1260** Progression of hand osteoarthritis over 2 years: a clinical and radiological follow-up study  
*S Botha-Scheepers, N Riyazi, I Watt, F R Rosendaal, E Slagboom, N Bellamy, F C Breedveld, M Kloppenburg*

- 1265** Opportunities for improving medication use and monitoring in gout  
*J A Singh, J S Hodges, S M Asch*

- 1271** Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis  
*B J Radovits, D A Popa-Diaconu, C Popa, A Eijsbouts, R F J M Laan, P L C M van Riel, J Fransen*

- 1277** Infliximab improves vascular stiffness in patients with rheumatoid arthritis  
*M Wong, S P Oakley, L Young, B Y Jiang, A Wierzbicki, G Panayi, P Chowienczyk, B Kirkham*

- 1285** Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy  
*K Pavelka, K Jarošová, D Suchý, L Šenolt, K Chroust, L Dušek, J Vencovský*

- 1290** Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography  
*N Dalbeth, B Clark, K Gregory, G Gamble, T Sheehan, A Doyle, F M McQueen*

- 1296** Does low-field dedicated extremity MRI (E-MRI) reliably detect bone erosions in rheumatoid arthritis? A comparison of two different E-MRI units and conventional radiography with high-resolution CT scanning  
*A Duer-Jensen, B Ejbjerg, E Albrecht-Beste, A Vestergaard, U Møller Døhn, M Lund Hetland, M Østergaard*

- 1303** A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue  
*A W R van Kuijk, D M Gerlag, K Vos, G Wolbink, M de Groot, M A de Rie, A H Zwinderman, B A C Dijkmans, P P Tak*

- 1310** Proposal for a new clinical entity, IgG<sub>4</sub>-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG<sub>4</sub>-related disorders  
*Y Masaki, L Dong, N Kurose, K Kitagawa, Y Morikawa, M Yamamoto, H Takahashi, Y Shinomura, K Imai, T Saeki, A Azumi, S Nakada, E Sugiyama, S Matsui, T Origuchi, S Nishiyama, I Nishimori, T Nojima, K Yamada, M Kawano, Y Zen, M Kaneko, K Miyazaki, K Tsubota, K Eguchi, K Tomoda, T Sawaki, T Kawanami, M Tanaka, T Fukushima, S Sugai, H Umehara*

- 1316** Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis  
*C A Wijbrandts, S I van Leuven, H D Boom, D M Gerlag, E G S Stroes, J J P Kastelein, P P Tak*

- 1322** Ultrasound validity in the measurement of knee cartilage thickness  
*E Naredo, C Acebes, I Möller, F Canillas, J J de Agustín, E de Miguel, E Filippucci, A Iagnocco, C Moragues, R Tuneu, J Uson, J Garrido, E Delgado-Baeza, I Sáenz-Navarro*

## Basic and translational research

- 1328** Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis  
*C Trocmé, H Marotte, A Baillet, B Pallot-Prades, J Garin, L Grange, P Miossec, J Tebib, F Berger, M J Nissen, R Juvin, F Morel, P Gaudin*

- 1334** Expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in long-standing ankylosing spondylitis  
*M Neidhart, X Baraliakos, C Seemayer, C Zelder, R E Gay, B A Michel, H Boehm, S Gay, J Braun*

### MORE CONTENTS ►



This article has been chosen by the editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtl>

C O P E

COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics


[www.publicationethics.org.uk](http://www.publicationethics.org.uk)



When you have finished with this please recycle it

- 1340** Evidence for association of an interleukin 23 receptor variant independent of the R381Q variant with rheumatoid arthritis  
*J E Hollis-Moffatt, M E Merriman, R A Rodger, K A Rowley, P T Chapman, N Dalbeth, P J Gow, A A Harrison, J Highton, P B B Jones, J L O'Donnell, L K Stamp, T R Merriman*
- 1345** Regulatory IL4+CD8+ T cells in patients with ankylosing spondylitis and healthy controls  
*L Zhang, L B Jarvis, H-J Baek, J S Hill Gaston*
- 1352** Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated by interleukins 2, 7 and 15  
*C Bocelli-Tyndall, L Bracci, S Schaeren, C Feder-Mengus, A Barbero, A Tyndall, G C Spagnoli*
- 1360** Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis  
*K Van Beneden, K Coppeters, W Laroy, F De Keyser, I E Hoffman, F Van den Bosch, B Vander Cruyssen, M Drennan, P Jacques, P Rottiers, G Verbruggen, R Contreras, N Callewaert, D Elewaut*
- 
- Letters**
- 1366** STAT4 single nucleotide polymorphism, rs7574865 G/T, as a risk for antiphospholipid syndrome  
*T Horita, T Atsumi, N Yoshida, H Nakagawa, H Kataoka, S Yasuda, T Koike*
- 1367** Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis  
*P Bohanec Grabar, B Rozman, D Logar, S Praprotnik, V Dolžan*
- 1368** A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis  
*B J F van den Bemt, K Vos, A A den Broeder, M Blom, R M Thurlings, G M Bartelds, S O Stapel, P Barrera, P P Tak, M T Nurmohamed, G-J Wolbink*
- 1369** High-resolution MRI for assessment of middle meningeal artery involvement in giant cell arteritis  
*T A Bley, J Geiger, S Jacobsen, O Wieben, M Markel, P Vaith, T Grist, M Langer, M Uhl*
- 1371** Optimisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A–677C alleles on probability to respond  
*W M Kooloos, J A M Wessels, S M van der Kooij, C F Allaart, T W J Huizinga, H-J Guchelaar*
- 1372** Changes in surgical intervention patterns in rheumatoid arthritis over 10 years in one centre  
*C Kolling, D B Herren, B R Simmen, J Goldhahn*
- 1373** A re-evaluation of three putative functional single nucleotide polymorphisms in rheumatoid arthritis  
*D Plant, A Barton, W Thomson, X Ke, S Eyre, A Hinks, J Bowes, L J Gibbons, A G Wilson, I Marinou, A W Morgan, S Steer, L J Hocking, D M Reid, P Wordsworth, P Harrison, J Worthington*
- 1375** Association of STAT4 polymorphism with systemic sclerosis in a Japanese population  
*N Tsuchiya, A Kawasaki, M Hasegawa, M Fujimoto, K Takehara, Y Kawaguchi, M Kawamoto, M Hara, S Sato*

## Take the pain out of research every month



Annals of the Rheumatic Diseases is the premier clinical rheumatology journal in Europe with an impressive impact factor of 6.411, so you'll want the guarantee of reading it every month.

Why not recommend the journal to your librarian or better still, obtain your own personal subscription? You will receive a paper copy every month as well as online access for **just £227 a year** (€306, \$443). Too much paper on your desk already? An online subscription is **just £106** (€143, \$207).

Visit [group.bmj.com/group/subs-sales](http://group.bmj.com/group/subs-sales) - your subscription to this first class journal is just a few clicks away.

[ard.bmj.com](http://ard.bmj.com) BMJ Journals